Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK
 

By selecting this, I agree to receive emails from celltelligence.com.


You will be granted access to your Celltelligence Library to view the full article after sign up.

Carvykti Meets Another Regulatory Milestone; LB1901’s FDA Clinical Hold Lifted; Legend Q1 2022 Earnings Summary

Here is a brief preview of this blast: On Wednesday, June 1, Legend released their Q1 2022 results (press release) highlighting Carvykti’s (cilta-cel; BCMA CAR-T) recent European Commission (EC) conditional marketing authorization in ≥4L r/r MM. Additionally, management confirmed that the FDA lifted the clinical hold on LB1901’s (LCAR-T2C; autologous CD4 CAR-T) Ph1 trial in r/r TCL. Below, Celltelligence provides insights on Carvykti’s EC approval, while discussing LB1901's FDA clinical hold lift.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.